Vitality Watch

Dossier clinicaltrials trial early 03-aug-2026
Small or early-phase human trial or pilot study

A Study of AMC6156 in People With Sarcopenia

Key claim: A randomized placebo-controlled trial is testing whether daily AMC6156 for 12 weeks is safe and can improve physical function and strength in older adults with sarcopenia.

Abstract

This clinical trial aims to find out whether AMC6156 can improve physical function and is safe in older adults with sarcopenia. Participants will take AMC6156 or a placebo daily for 12 weeks, and their movement, strength, and safety will be regularly monitored through tests and checkups.

Why this matters

Sarcopenia remains a healthspan-limiting condition with no approved pharmacotherapy, so any early placebo-controlled human trial of a novel candidate is a meaningful pipeline signal in this area. However, this entry is a protocol description rather than a results readout, so it registers as trial activity — not evidence of benefit — and belongs alongside other sarcopenia-directed candidates being tracked for eventual outcome data.

Source

Link

Briefing card

A Study of AMC6156 in People With Sarcopenia
Stage: trial early · clinicaltrials · 03-aug-2026

A randomized placebo-controlled trial is testing whether daily AMC6156 for 12 weeks is safe and can improve physical function and strength in older adults with sarcopenia.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: nct:NCT07072195

build build 880 · 2bcef25 · 2026-11-18